5-氨基-[1,1'-联苯]-2-甲酸甲酯 | 51990-95-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-[1,1'-联苯]-2-甲酸甲酯
• 英文名称: 2-phenyl-4-aminobenzoic acid methyl ester
• 英文别名: methyl 5-amino-[1,1'-biphenyl]-2-carboxylate；5-amino-biphenyl-2-carboxylic acid methyl ester；methyl 4-amino-2-phenylbenzoate
• CAS: 51990-95-5
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: RCQJWALJLIKPAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-氨基-[1,1'-联苯]-2-甲酸甲酯 在 硫酸 、 sodium nitrite 、 氢溴酸 、 copper(I) bromide 作用下， 以 水 、 乙腈 为溶剂， 反应 4.5h， 以98.9%的产率得到methyl 5-bromo-[1,1'-biphenyl]-2-carboxylate
  参考文献：
  名称：

  一种3-卤代芴酮类化合物的制备方法

  摘要：

  本发明涉及一种3-卤代芴酮类化合物的制备方法，本方法以2-溴-4-硝基苯甲酸甲酯为起始原料，经Suzuki反应、还原反应、重氮化反应以及关环反应制备通式3-卤代芴酮类化合物。采用本发明方法合成3-卤代芴酮，成本低、条件温和、操作简单、适合实验室以及工业化大规模制备。

  公开号：

  CN105294415A
• 作为产物：
  描述：

  2-溴-4-硝基苯甲酸甲酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 5-氨基-[1,1'-联苯]-2-甲酸甲酯
  参考文献：
  名称：

  [EN] MODIFIED PROTEINS AND PROTEIN DEGRADERS
  [FR] PROTÉINES MODIFIÉES ET AGENTS DE DÉGRADATION DE PROTÉINES

  摘要：

  本文提供了结合或降解靶蛋白的化合物、药物组合物和方法。本文还提供了具有DNA损伤结合蛋白1（DDB1）结合基团的化合物。其中一些实施例包括连接物。其中一些实施例包括靶蛋白结合基团。本文还提供了配体-DDB1复合物。本文还提供了体内修饰的DDB1蛋白。

  公开号：

  WO2021239117A1

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• Compounds and methods for the inhibition of compounds cruzi
  申请人：Hamilton D Andrew

  公开号：US20060167269A1

  公开（公告）日：2006-07-27

  The present invention relates to compounds according to the formula (I): Where R A is a C 1 -C 10 substituted or unsubstituted linear, branch-chained or cyclic alkyl or alkenyl group or a phenyl group according to the formula (II): R B is a C 1 -C 10 substituted or unsubstituted linear, branch-chained or cyclic alkyl or alkenyl group or a phenyl group of the formula (III): R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each independently selected from H, C 1 -C 10 (preferably a C 1 -C 4 ) alkyl or alkenyl group, CF 3 , F, Cl, Br, I, CN, NO 2 , NH 2 , NHR, NRR, COR (acyl group), OR (hydroxyl or ether group), CO 2 R (carboxylic acid or ester group), or COSR (thioester group) where R is H or a C 1 -C 10 (preferably a C 1 -C 4 ) alkyl or alkenyl group, an unsubstituted or substituted aryl (preferably, phenyl) or heterocycle group, or a (IV) group, where R 3 is H, a C 1 -C 10 (preferably a C 1 -C 4 ) alkyl, alkenyl, ether or a thioether group; and R 11 and R 12 are independently selected from H or a C 1 -C 3 alkyl or alkenyl group, or a pharmaceutically acceptable salt thereof and methods for treating infections caused by protozoal, fungal and/or bacterial agents such as Trypanosoma cruzi, Mycobacterium spp., Leishmania spp., Cryptococcus spp., Aspergillus spp., Histoplasma spp., Candida spp., especially Candida albicans, Pneumocystis carinii, Trichophyton spp., Microsporum spp., Malassezia spp., Rhizopus spp., Pseudallescheria spp., Blastomyces dermatitidis and Coccidiodes spp., among others.

  本发明涉及式(I)的化合物：其中RA是C1-C10取代或未取代的线性、支链或环烷基或烯基或式(II)的苯基：RB是C1-C10取代或未取代的线性、支链或环烷基或烯基或式(III)的苯基：R1、R2、R3、R4、R5、R6、R7、R8、R9和R10各自独立地选自H、C1-C10(优选为C1-C4)烷基或烯基、CF3、F、Cl、Br、I、CN、NO2、NH2、NHR、NRR、COR（酰基）、OR（羟基或醚基）、CO2R（羧酸或酯基）或COSR（硫酯基），其中R是H或C1-C10(优选为C1-C4)烷基或烯基、未取代或取代的芳基（优选为苯基）或杂环基，或式(IV)的基团，其中R3是H、C1-C10(优选为C1-C4)烷基、烯基、醚或硫醚基；R11和R12各自独立地选自H或C1-C3烷基或烯基，或其药学上可接受的盐，以及用于治疗由原虫、真菌和/或细菌引起的感染的方法，例如Trypanosoma cruzi，Mycobacterium spp.，Leishmania spp.，Cryptococcus spp.，Aspergillus spp.，Histoplasma spp.，Candida spp.，特别是Candida albicans，Pneumocystis carinii，Trichophyton spp.，Microsporum spp.，Malassezia spp.，Rhizopus spp.，Pseudallescheria spp.，Blastomyces dermatitidis和Coccidioides spp.等。
• [EN] HISTONE DEACETYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：UNIV QUEENSLAND

  公开号：WO2022133551A1

  公开（公告）日：2022-06-30

  The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for inhibiting Class IIa versus Class I HDACs. The present application also relates to methods of using the compounds and to uses of the compounds, especially in relation to the prevention of a disease, disorder or condition associated with Class IIa HDAC activity. In one form, the compounds are (ortho-phenyl) phenyl hydroxamates. In another form, the compounds are as provided in Formula (I), wherein R1 is a phenyl or cycloalkenyl which may be optionally substituted. Formula (I)

  本申请涉及抑制组蛋白去乙酰化酶（HDAC）结合或功能的化合物，药学上可接受的盐或其前药。这些化合物可能具有一定的选择性，能够抑制IIa类与I类HDAC。本申请还涉及使用这些化合物的方法和用途，尤其是与预防与IIa类HDAC活性相关的疾病、疾病或病情有关的用途。在一种形式中，这些化合物是（邻苯基）苯基羟肟酸酯。在另一种形式中，这些化合物如公式（I）所示，其中R1是苯基或环烯基，可选择性地取代。
• Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease
  作者：Praveen Kumar Suryadevara、Srinivas Olepu、Jeffrey W. Lockman、Junko Ohkanda、Mandana Karimi、Christophe L. M. J. Verlinde、James M. Kraus、Jan Schoepe、Wesley C. Van Voorhis、Andrew D. Hamilton、Frederick S. Buckner、Michael H. Gelb

  DOI：10.1021/jm900030h

  日期：2009.6.25

  We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14 alpha-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T cruzi amastigotes in vitro with values of EC50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.
• INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES
  申请人：UNIVERSITY OF PITTSBURGH

  公开号：EP0873123B1

  公开（公告）日：2003-04-09